Australia markets closed

Evoke Pharma Inc (EV00.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
0.5500+0.0350 (+6.80%)
At close: 03:30PM CET
Full screen
Previous close0.5150
Open0.5300
Bid0.5250 x N/A
Ask0.6050 x N/A
Day's range0.5300 - 0.5500
52-week range0.5100 - 2.0400
Volume0
Avg. volume0
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date13 May 2024 - 17 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer

    SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that Matthew J. D’Onofrio will be succeeding David A. Gonyer as Chief Executive Officer as of March 31, 2024 upon Mr. Gonyer’s departure for personal reasons. Mr. D’Onofrio currently serves as President and Chief Operating Officer. “Worki

  • Simply Wall St.

    Evoke Pharma, Inc. (NASDAQ:EVOK): Are Analysts Optimistic?

    We feel now is a pretty good time to analyse Evoke Pharma, Inc.'s ( NASDAQ:EVOK ) business as it appears the company...

  • Insider Monkey

    Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2023 Earnings Call Transcript

    Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2023 Earnings Call Transcript March 14, 2024 Evoke Pharma, Inc. misses on earnings expectations. Reported EPS is $-0.59 EPS, expectations were $-0.5. Evoke Pharma, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, […]